NCT01335269 - A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions

Neoplasms

Interventions

DRUG

BI 853520

BI 853520 once daily in a dose escalation schedule

Trial Locations (5)

1300.2.1002 Boehringer Ingelheim Investigational Site, Hamilton

1300.2.1001 Boehringer Ingelheim Investigational Site, Toronto

1300.2.31003 Boehringer Ingelheim Investigational Site, Amsterdam

1300.2.31001 Boehringer Ingelheim Investigational Site, Rotterdam

1300.2.31002 Boehringer Ingelheim Investigational Site, Utrecht